HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ng, C. S. Articles by Tannir, N. M. Search for Related Content PubMed PubMed Citation Articles by Ng, C. S. Articles by Tannir, N. M. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

Perfusion CT in Patients With Metastatic Renal Cell Carcinoma Treated With Interferon

¹ Department of Diagnostic Radiology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 368, Houston, TX 77030-4009.
² Department of Diagnostic Radiology, Cancer Hospital Fudan University, Shanghai, China.
³ Quantitative Sciences Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
⁴ Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

OBJECTIVE. The objective of our study was to assess the potential value of tumor perfusion parameters measured by perfusion CT as possible biomarkers of prognosis and early indicator of treatment efficacy in patients with metastatic conventional renal cell carcinoma (RCC) treated with interferon.

MATERIALS AND METHODS. This study comprised 37 patients with metastatic RCC who were enrolled in a larger (n = 118) randomized clinical trial of intermediate- versus low-dose interferon. Tumor perfusion parameters—that is, tumor blood flow, blood volume, mean transit time (MTT), and permeability–surface area product—of index metastatic lesions were obtained at baseline and at 8-week follow-up. Baseline perfusion parameters and changes at follow-up were compared, and their associations with patient progression-free survival were estimated. Univariate and multivariate analyses were performed.

RESULTS. Twenty-eight patients were assessable. Median progression-free survival was 5.3 months (95% CI, 2.4–7.4 months), with one partial response. Tumor blood flow at baseline was inversely associated with patient progression-free survival in both univariate (hazard ratio [HR] = 1.006, p = 0.025) and multivariate (HR = 1.007, p = 0.012) analyses. There were significant increases in tumor blood flow and reductions in MTT on follow-up scans compared with baseline scans (both, p = 0.04), but no association between changes in perfusion parameters and progression-free survival was detected.

CONCLUSION. Patients with highly vascularized metastatic RCC as shown by high baseline tumor blood flow appear to have a worse prognosis than those who do not. Tumor perfusion may be a useful biomarker of prognosis and additionally, in the future, may assist in treatment stratification. The potential utility of perfusion CT as an early response indicator was probably inadequately assessed in this study because of the limited antiangiogenic activity of interferon in metastatic RCC.

Keywords: biomarkers • interferon • metastatic renal cell carcinoma • perfusion CT • renal cell carcinoma • tumor perfusion

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?